DDInter840 DDInter1763
A serotonin receptor (5HT-3 selective) antagonist that has been used as an antiemetic and antinauseant for cancer chemotherapy patients.
Temsirolimus is a derivative of sirolimus used in the treatment of renal cell carcinoma (RCC). It was developed by Wyeth Pharmaceuticals under the trade name Torisel. Temsirolimus was approved by the FDA in late May 2007 as well as the European Medicines Agency (EMEA) on November 2007.
Granisetron {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Granisetron {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Temsirolimus
Granisetron {u} (Compound) upregulates {v} (Gene) CASP10
CASP10 {u} (Gene) is upregulated by {v} (Compound) Temsirolimus
Granisetron {u} (Compound) downregulates {v} (Gene) RPS4Y1
RPS4Y1 {u} (Gene) is downregulated by {v} (Compound) Temsirolimus
Granisetron {u} (Compound) causes {v} (Side Effect) Pain
Pain {u} (Side Effect) is caused by {v} (Compound) Temsirolimus
Granisetron {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Everolimus
Everolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Granisetron {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Everolimus
Everolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Granisetron {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) covaries with {v} (Gene) YRDC
YRDC {u} (Gene) is downregulated by {v} (Compound) Temsirolimus
Granisetron {u} (Compound) upregulates {v} (Gene) CASP10
CASP10 {u} (Gene) is upregulated by {v} (Compound) Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Granisetron {u} (Compound) upregulates {v} (Gene) MMP2
MMP2 {u} (Gene) regulates {v} (Gene) CES1
CES1 {u} (Gene) is upregulated by {v} (Compound) Temsirolimus
Granisetron may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Temsirolimus (Compound)
Granisetron (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Temsirolimus (Compound)
Granisetron (Compound) upregulates CASP10 (Gene) and CASP10 (Gene) is upregulated by Temsirolimus (Compound)
Granisetron (Compound) downregulates RPS4Y1 (Gene) and RPS4Y1 (Gene) is downregulated by Temsirolimus (Compound)
Granisetron (Compound) causes Pain (Side Effect) and Pain (Side Effect) is caused by Temsirolimus (Compound)
Granisetron may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Everolimus (Compound) and Everolimus (Compound) resembles Temsirolimus (Compound)
Granisetron (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Everolimus (Compound) and Everolimus (Compound) resembles Temsirolimus (Compound)
Granisetron (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) covaries with YRDC (Gene) and YRDC (Gene) is downregulated by Temsirolimus (Compound)
Granisetron (Compound) upregulates CASP10 (Gene) and CASP10 (Gene) is upregulated by Sirolimus (Compound) and Sirolimus (Compound) resembles Temsirolimus (Compound)
Granisetron (Compound) upregulates MMP2 (Gene) and MMP2 (Gene) regulates CES1 (Gene) and CES1 (Gene) is upregulated by Temsirolimus (Compound)